A Selective α7 Nicotinic Acetylcholine Receptor Agonist, PNU-282987, Attenuates ILC2s Activation and Alternaria-Induced Airway Inflammation
Open Access
- 1 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
Background: The anti-inflammatory effect of an α7nAChR agonist, PNU-282987, has previously been explored in the context of inflammatory disease. However, the effects of PNU-282987 on type 2 innate lymphoid cells (ILC2s)-mediated allergic airway inflammation has not yet been established.Aims: To determine the effects of PNU-282987 on the function of ILC2s in the context of IL-33– or Alternaria Alternata (AA)– induced airway inflammation.Methods: PNU-282987 was administered to mice that received recombinant IL-33 or AA intranasal challenges. Lung histological analysis and flow cytometry were performed to determine airway inflammation and the infiltration and activation of ILC2s. The previously published α7nAChR agonist GTS-21 was employed as a comparable reagent. ILC2s were isolated from murine lung tissue and cultured in vitro in the presence of IL-33, IL-2, and IL-7 with/without either PNU-282987 or GTS-21. The expression of the transcription factors GATA3, IKK, and NF-κB were also determined.Results: PNU-282987 and GTS-21 significantly reduced goblet cell hyperplasia in the airway, eosinophil infiltration, and ILC2s numbers in BALF, following IL-33 or AA challenge. In vitro IL-33 stimulation of isolated lung ILC2s showed a reduction of GATA3 and Ki67 in response to PNU-282987 or GTS-21 treatments. There was a significant reduction in IKK and NF-κB phosphorylation in the PNU-282987–treated group when compared to the GTS-21–treated ILC2s.Conclusion: PNU-282987 inhibits ILC2-associated airway inflammation, where its effects were comparable to that of GTS-21.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitisJournal of Experimental Medicine, 2013
- TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin InflammationScience Translational Medicine, 2013
- IL-33 is a crucial amplifier of innate rather than acquired immunityProceedings of the National Academy of Sciences, 2010
- The many paths to asthma: phenotype shaped by innate and adaptive immunityNature Immunology, 2010
- Nuocytes represent a new innate effector leukocyte that mediates type-2 immunityNature, 2010
- Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cellsNature, 2009
- Role of adapters in Toll-like receptor signallingBiochemical Society Transactions, 2003
- IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In VivoImmunity, 2001
- Interleukin-13: Central Mediator of Allergic AsthmaScience, 1998
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.Journal of Experimental Medicine, 1996